You are here
Clinical Trial Data Should Be Accessible and Transparent
At Pfizer we believe all participants should have access to clinical trial data to advance medical understanding and promote data transparency.
Pfizer believes that it is important for researchers, trial participants, regulators, and others acting in the best interest of patients to have access to clinical trial information to advance medical understanding and progress. It’s also important that this access works in ways that protect patient privacy, preserve regulatory authority and maintain incentives for those who generate data to conduct new research.
Pfizer publicly shares results from our clinical trials, whether the results are neutral, negative or positive. We also share data gathered in clinical trials we sponsor with trial volunteers, researchers, and others.
There are several ways in which we share trial results and data: